Nerisona (Diflucortolone Valerate)

Diflucortolone valerate, the active ingredient in Nerisona, is a corticosteroid presented as a topical formulation for skin application. It is used to manage inflammatory skin conditions such as psoriasis, eczema and dermatitis, providing anti‑inflammatory and immunosuppressive effects in affected areas.

GNH USA supplies Nerisona as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and ensuring consistent batch release for global distribution.

Diflucortolone valerate is a potent topical corticosteroid indicated for several inflammatory skin disorders.

Psoriasis: reduces scaling, erythema and plaque thickness, improving skin appearance. Eczema: alleviates itching, redness and edema associated with atopic dermatitis. Dermatitis: controls inflammation and pruritus in contact or seborrheic dermatitis. Other inflammatory skin disorders: provides symptomatic relief in conditions such as lichen planus or discoid lupus erythematosus.

Topical application of diflucortolone valerate may be associated with local and systemic adverse reactions.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Dryness or peeling of the treated skin. - Mild erythema or redness. - Pruritus or itching.

Serious or Rare Side Effects: - Secondary infection of the skin, including bacterial, fungal or viral. - Hypersensitivity reactions such as contact dermatitis, urticaria or angioedema. - Systemic effects like adrenal suppression with extensive or prolonged use.

When using diflucortolone valerate, consider the following safety measures.

Application area: limit to affected skin and avoid occlusion unless directed. Duration: use for the shortest period necessary; prolonged use increases risk of skin atrophy. Age: avoid use in children unless prescribed, as skin is more susceptible. Concomitant therapy: do not combine with other potent topical steroids without medical supervision. Systemic absorption: monitor for signs of hypothalamic‑pituitary‑adrenal axis suppression in extensive treatment. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Diflucortolone valerate may interact with other medicines; awareness helps prevent complications.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of systemic side effects. - CYP3A4 inhibitors (e.g., ketoconazole): may raise local drug levels, enhancing adverse effects. - Immunosuppressants (e.g., cyclosporine): may potentiate immunosuppression and infection risk.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial topical agents: may alter skin barrier and affect absorption. - Phototherapy: combined use can increase skin irritation. - Topical non‑steroidal anti‑inflammatory drugs: monitor for additive irritation.